Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners

Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's National Practitioner Network

WASHINGTON, Conn. and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases today announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, a leading marketplace that enables functional and integrative medicine practitioners to easily discover, order and manage advanced diagnostic testing solutions.

Through this collaboration, 20/20 BioLabs' testing solutions will gain broader visibility and accessibility across Evexia's network of more than 40,000 functional and integrative medicine practitioners, helping support expanded adoption among providers seeking advanced tools to better assess patient health and inform care decisions.